Clinical Pharmacy Program Guidelines for Kineret -ARIZONA

<table>
<thead>
<tr>
<th>Program</th>
<th>Prior Authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication</td>
<td>Kineret (anakinra)</td>
</tr>
</tbody>
</table>

1. **Background:**

Indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying anti-rheumatic drugs (DMARDs). Kineret can be used alone or in combination with DMARDs other than Tumor Necrosis Factor (TNF) blocking agents.

Indicated for the treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).

**Off Label Uses**

**Systemic Juvenile Idiopathic Arthritis**

Has been used for the treatment of systemic juvenile idiopathic arthritis.

2. **Coverage Criteria:**

A. **Rheumatoid Arthritis (RA)**

1. **Initial Authorization**

   a. Diagnosis of moderately to severely active RA

   -AND-

   b. Prescribed or recommended by a rheumatologist

   -AND-

   c. History of failure, contraindication, or intolerance to one non-biologic disease modifying anti-rheumatic drug (DMARD) [eg, methotrexate, leflunomide, sulfasalazine, hydroxychloroquine]

   -AND-

   d. Patient is not receiving Kineret in combination with any of the following:

   (1) Biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab),
Cimzia (certolizumab), Simponi (golimumab)
(2) Janus kinase inhibitor [eg, Xeljanz (tofacitinib)]
(3) Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

-AND-

e. One of the following:

(1) History of failure, contraindication, or intolerance to both of the following:

(a) Humira (adalimumab)
(b) Enbrel (etanercept)

-OR-

(2) For continuation of prior Kineret therapy

Authorization will be issued for 12 months.

2. Reauthorization

a. Documentation of positive clinical response to Kineret therapy

-AND-

b. Patient is not receiving Kineret in combination with any of the following:

(1) Biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
(2) Janus kinase inhibitor [eg, Xeljanz (tofacitinib)]
(3) Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

Authorization will be issued for 12 months.

B. Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

1. Initial Authorization

a. Diagnosis of neonatal-onset multisystem inflammatory disease (NOMID)

-AND-
b. Diagnosis of NOMID has been confirmed by one of the following:
   (1) NLRP-3 (nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Auto-inflammatory Syndrome-1 [CIAS1]) mutation
   -OR-
   (2) Evidence of active inflammation which includes both of the following:
      (a) Clinical symptoms (e.g., rash, fever, arthralgia)
      (b) Elevated acute phase reactants (e.g., ESR, CRP)
   -AND-

c. Prescribed or recommended by one of the following:
   (1) Allergist/Immunologist
   (2) Rheumatologist
   -AND-

d. Patient is not receiving Kineret in combination with any of the following:
   (1) Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
   (2) Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
   (3) Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

Authorization will be issued for 12 months.

2. Reauthorization

a. Documentation of positive clinical response to Kineret therapy
   -AND-

b. Patient is not receiving Kineret in combination with any of the following:
   (1) Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
   (2) Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
   (3) Phosphodiesterase 4 (PDE4) inhibitor [e.g., Otezla (apremilast)]

Authorization will be issued for 12 months.
C. Systemic Juvenile Idiopathic Arthritis (SJIA) (off-label)

1. Initial Authorization
   a. Diagnosis of active systemic juvenile idiopathic arthritis
   -AND-
   b. Prescribed or recommended by a rheumatologist
   -AND-
   c. History of failure, contraindication, or intolerance to one of the following:
      (1) Non-steroidal anti-inflammatory drugs (NSAIDs) [eg, Motrin (ibuprofen), Naprosyn (naproxen)]
      (2) Corticosteroids (eg, prednisone)
   -AND-
   d. Patient is not receiving Kineret in combination with any of the following:
      (1) Biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
      (2) Janus kinase inhibitor [eg, Xeljanz (tofacitinib)]
      (3) Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

Authorization will be issued for 12 months.

2. Reauthorization
   a. Documentation of positive clinical response to Kineret therapy
   -AND-
   b. Patient is not receiving Kineret in combination with any of the following:
      (1) Biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]
      (2) Janus kinase inhibitor [eg, Xeljanz (tofacitinib)]
      (3) Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

Authorization will be issued for 12 months.
3. References:

<table>
<thead>
<tr>
<th>Program</th>
<th>Program type – Prior Authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Change Control</strong></td>
</tr>
<tr>
<td>Date</td>
<td>Change</td>
</tr>
<tr>
<td>August 2017</td>
<td>New policy specific to Arizona</td>
</tr>
</tbody>
</table>